Loss of H3K27me3 in WHO grade 3 meningioma

Loss of H3K27me3 in WHO grade 3 meningioma

Immunohistochemical quantification of H3K27me3 was reported to distinguish meningioma patients with an unfavorable prognosis but is not yet established as a prognostic biomarker within WHO grade 3 meningiomas. We studied H3K27me3 loss in a series of biopsies from primary and secondary malignant meni...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain tumor pathology 2022-10, Vol.39 (4), p.200-209
Hauptverfasser: Maier, Andrea Daniela, Brøchner, Christian Beltoft, Mirian, Christian, Haslund-Vinding, Jeppe, Bartek, Jiri, Ekström, Tomas J., Poulsen, Frantz Rom, Scheie, David, Mathiesen, Tiit
Format: Artikel
Sprache:eng
Schlagworte:
Automation
Biomarkers
Brain cancer
Cancer Research
Cloning
Genotype & phenotype
Medical prognosis
Medicine
Medicine & Public Health
Mutation
Neurology
Neurosurgery
Oncology
Original Article
Pathology
Patients
Pediatrics
Surgery
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Immunohistochemical quantification of H3K27me3 was reported to distinguish meningioma patients with an unfavorable prognosis but is not yet established as a prognostic biomarker within WHO grade 3 meningiomas. We studied H3K27me3 loss in a series of biopsies from primary and secondary malignant meningioma to validate its prognostic performance and describe if loss of H3K27me3 occurs during malignant transformation. Two observers quantified H3K27me3 status as “complete loss”,  50% stained cells in 110 tumor samples from a population-based consecutive cohort of 40 WHO grade 3 meningioma patients. We found no difference in overall survival (OS) in patients with > 50% H3K27me3 retention compared to 
ISSN:1433-7398
1861-387X
DOI:10.1007/s10014-022-00436-3